RESEARCH CENTER – CLINICAL TRIALS
ACCESS TO THE LATEST
TREATMENTS
Oregon Urology Institute is committed to advancing the standard of care in treating urological disorders and cancers. To achieve this, we are deeply involved in research at our urology clinic. This gives our patients access to experimental procedures and treatments that wouldn’t otherwise be available.
If you’d like to join one of the trials at our urology clinic, your doctor can help determine if you’re a candidate. Qualified candidates will be informed about potential risks and benefits. Our clinical trial participants are carefully monitored, and you can opt out at any time.
CURRENTLY
ENROLLING
Here are trials we’re currently conducting at our urology clinic. Ask your doctor for more information if you’re interested in participating.
PSMA DC – Novartis D
- Study Type: Interventional (Clinical Trial)
- Study Design:
- Estimated Enrollment: 450 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Official Title: An International, Prospective, Open-label, Multicenter, Randomized Phase Ill Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
- Clinicaltrials.gov link: https://clinicaltrials.gov/
study/NCT05939414
PSMACare – Novartis B
- Study Type: Interventional (Clinical Trial)
- Study Design:
- Estimated Enrollment: 120 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Official Title: An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of lutetium (177Lu) vipivotide tetraxetan (AAA617) alone and lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway Inhibitors in patients with PSMA PET scan positive Castration-Resistant Prostate Cancer
- Clinicaltrials.gov link: https://clinicaltrials.gov/
study/NCT05849298
CG Oncology - PIVOT-006
- Study Type: Interventional (Clinical Trial)
- Study Design:
- Estimated Enrollment: 364 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Official Title: A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
- Clinicaltrials.gov link: https://clinicaltrials.gov/
study/NCT06111235
Debio 4228-201
- Study Type: Interventional (Clinical Trial)
- Study Design:
- Estimated Enrollment: 60 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Official Title: A Phase 2, randomized, open-label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with locally advanced/metastatic prostate cancer
- Clinicaltrials.gov link: https://clinicaltrials.gov/
study/NCT06395753
GIAnomics
- Study Type: Observational (Genetic Testing)
- Study Design:
- Estimated Enrollment: 3000 participants
- Allocation: N/A
- Intervention Model: N/A
- Masking: None
- Primary Purpose: Diagnosis and Risk Assessment
- Official Title: Genetic Susceptibility and Management of Chronic Disease
- Link to sponsor page: https://www.genlabus.com/2020/
03/12/designer-genomics- international-selects- genetics-institute-of-america- as-irb-approved-laboratory- for-inflammasome-study/
ONGOING STUDIES
NOT ENROLLING
Bladder Cancer-KN676
Study Type: Interventional (Clinical Trial)
Study Design:
- Estimated Enrollment: 1045 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676)
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–ATLAS
Study Type: Interventional
Study Design:
- Allocation: Randomized
- Actual Enrollment: 1503 Participants
- Intervention Model: Parallel Assignment
- Masking: Double Blind (Subject, Investigator)
- Primary Purpose: Treatment
Official Title: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy.
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–DAROL
Study Type: Observational
Study Design:
- Observational Model: Cohort
- Time Perspective: Prospective
- Estimated Enrollment: 1000 participants
Official Title:Darolutamide Observational Study in Non-metastatic Castration-resistant
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–EMBARK
Study Type: Interventional
Study Design:
- Actual Enrollment: 1068 participants
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy)
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–PRIMORDIUM
Study Type: Interventional
Study Design:
- Enrollment Estimate: 412 participants
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Official Title: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–SAFELY
Study Design:
- Observational Model: Cohort
- Time Perspective: Prospective
- Estimated Enrollment: 600 participants
- Target Follow-Up Duration: 10 Years
- Official Title: A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–ULYSSES
Study Type:
Interventional
Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title:
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
For more information on this study, visit clinicaltrials.gov
URETHRAL STRICTURE–ROBUST III
Study Type: Interventional
Study Design:
Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment
Official Title:
ROBUST III – Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease – A Randomized Control Trial
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–TAK-RAD
Study Type:
Interventional
Study Design:
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
For more information on this study, visit clinicaltrials.gov
RESEARCH TEAM
VICTORIA EVANS
Clinical Research Director
KATAREANNA JEUDY
Regulatory Compliance Specialist II
MAX DIMARCO
Clinical Research Coordinator II
CORDELL CHASE
CTMS Coordinator
CONTACT US
2400 HARTMAN LANE,
SPRINGFIELD, OR 97477
PHONE: 541.334.3350
TOLL FREE: 1.800.246.9925
FAX: 541.343.3459
FIND US
JOIN OUR TEAM
